A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis

Al-Mutairi, Nawaf; Eassa, Bayoumy Ibrahim

doi:10.1080/14712598.2021.1843629

Cited by 16 publications

(8 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…35 Secukinumab (anti-IL 17A monoclonal antibody) showed similar efficacy and safety as ixekizumab in treating genital psoriatic lesions in an open label randomized controlled study in 2021. 36 Ustekinumab (an anti-IL 12/23 monoclonal antibody) has proved to be efficient in treating genital psoriasis. 37 Guselkumab was used with good results in an observational study conducted to assess its effectiveness and impact on quality of life of patients with genital and facial psoriasis.…”

Section: General Advicementioning

confidence: 99%

“…Ixekizumab (an anti‐IL 17A monoclonal antibody) showed improvement of genital erosions, ulcers, fissures, pruritus and sexual life in a randomized, double‐blinded placebo‐controlled phase 3 trial in 2018 35 . Secukinumab (anti‐IL 17A monoclonal antibody) showed similar efficacy and safety as ixekizumab in treating genital psoriatic lesions in an open label randomized controlled study in 2021 36 . Ustekinumab (an anti‐IL 12/23 monoclonal antibody) has proved to be efficient in treating genital psoriasis 37 .…”

Section: Clinical Featuresmentioning

confidence: 99%

See 1 more Smart Citation

2021 European guideline for the management of vulval conditions

Meijden

Boffa

Harmsel

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Dr Lewis has received royalties for contribution to textbooks A Practical Guide to Vulval Disease. Ridley's 'The Vulva' 3 rd edition and honoraria for teaching on dermatology. She is a Council member of the European College for the Study of Vulval Disease. Professor Tiplica has received lecture honoraria from Antibiotice SA and Novartis Pharma. He is chair of IUSTI Europe and president of the Romanian Association of Dermato-Venereologists. Dr Sherrard is a Member of the European Sexually Transmitted Infections Guidelines Editorial Board; and she is an officer of the International Union against Sexually Transmitted Infections (membership secretary

show abstract

Section: General Advicementioning

confidence: 99%

Section: Clinical Featuresmentioning

confidence: 99%

2021 European guideline for the management of vulval conditions

Meijden

Boffa

Harmsel

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Первый возрастной пик заболеваемости псориазом приходится на возраст от 15 до 30 лет, и именно в этот период наиболее вероятно развитие проблем, связанных с сексуальным благополучием и негативным влиянием на начало и/или поддержание межличностных отношений [26]. Обсуждаемое исследование [25] еще раз подтверждает, что развитие псориаза гениталий также ложится тяжелым бременем на пациентов среднего работоспособного возраста, что не может не актуализировать дополнительно данную проблему для сообщества. Сексуальная жизнь у пациентов с псориатическим поражением кожи гениталий становится сложной задачей не только из-за наличия высыпаний в этой локализации, но и из-за высокой частоты сопутствующих симптомов -зуда половых органов, боли, ощущения покалывания, шелушения и даже кровотечения.…”

Section: Discussionunclassified

“…В открытом рандомизированном контролируемом сравнительном исследовании оценивалось влияние иксекизумаба и секукинумаба как на состояние кожных проявлений, так и на сексуальную функцию у взрослых пациентов с псориазом гениталий средней и тяжелой степени тяжести [25]. Пациенты случайным образом были распределены в две равные группы.…”

Section: дизайн сравнительного исследования ингибиторов ил-17а в терапии псориаза половых органовunclassified

Clinical evidence of therapy for genital psoriasis by biologic agents

Sokolovskiy

Кохан

2021

Vestnik dermatologii i venerologii

View full text Add to dashboard Cite

Data in the scientific literature on the use of biologic therapy in localized forms of psoriasis elucidate mostly the problems of treatment of palmoplantar, scalp psoriasis and nail psoriasis. At the same time, the number of scientific data on the effect of biological therapy on genital psoriasis is extremely limited. Important that the quality of life on patients with genital psoriasis has very low level, which indicates a significant influence on the psychological and social well-being. At the same time, the limited number of therapeutic approaches makes this problem even more urgent. Unfortunately, special clinical trials for such patients are rather an exception. Ixekizumab has been reported an effectiveness for patients with anogenital psoriasis. New data on the comparative efficacy of ixekizumab and secukinumab give hope us for new opportunity for the treatment of genital psoriasis.

show abstract

“…43 Since then, smaller reallife case studies have shown similar results and good safety profile for Ixekizumab, with the most common adverse events including diarrhoea, injection site reactions, nasopharyngitis, upper respiratory tract infections and headaches. 39,42,[44][45][46] One small head-to-head comparison study found the greatest clinical benefit in genital psoriasis symptoms with anti-IL17 (ixekizumab, secukinumab) and anti-IL12/23 (ustekinumab) when compared with TNF-a (adalimumab, etanercept, certolizumab). Ongoing trials include a cohort study evaluating the efficacy and impact on quality of life of guselkumab in study for patients with moderate facial and/or genital psoriasis (GULLIVER; NCT04439526).…”

Section: Systemic Treatmentsmentioning

confidence: 99%

Adult genital psoriasis: An updated review for clinicians

Wu,

Fischer

2024

Aust J Dermatology

View full text Add to dashboard Cite

Genital psoriasis is a chronic inflammatory skin condition that has been reported in up to 63% of patients with psoriasis on other parts of their skin. It has a profound impact on quality of life and sexual function which is often overlooked by current severity scores. Despite its prevalence and disease burden, genital psoriasis remains largely under‐reported and under‐treated. Historically, this was due to the impracticality and limited efficacy data of standard psoriasis treatments when applied to genital skin. However, there have been recent advancements with several new agents currently being developed and evaluated for genital psoriasis. This clinical review aims to provide an overview of the current evidence regarding the clinical features of genital psoriasis, available management options and tools for assessing patients' quality of life. Key takeaways from this review emphasise the recognition of genital psoriasis as a chronic and debilitating condition, unique in its impact on patients' quality of life, necessitating sensitive and attentive approaches to address their needs.

show abstract

A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis

Cited by 16 publications

References 46 publications

2021 European guideline for the management of vulval conditions

2021 European guideline for the management of vulval conditions

Clinical evidence of therapy for genital psoriasis by biologic agents

Adult genital psoriasis: An updated review for clinicians

Contact Info

Product

Resources

About